截止目前,引用Bioss產(chǎn)品發(fā)表的文獻(xiàn)共25359篇,總影響因子119363.29分,發(fā)表在Nature, Science, Cell以及Immunity等頂級(jí)期刊的文獻(xiàn)共59篇,合作單位覆蓋了清華、北大、復(fù)旦、華盛頓大學(xué)、麻省理工學(xué)院、東京大學(xué)以及紐約大學(xué)等國際研究機(jī)構(gòu)上百所。
我們每月收集引用Bioss產(chǎn)品發(fā)表的文獻(xiàn)。若您在當(dāng)月已發(fā)表SCI文章,但未被我公司收集,請(qǐng)致電Bioss,我們將贈(zèng)予現(xiàn)金鼓勵(lì),金額標(biāo)準(zhǔn)請(qǐng)參考“發(fā)文章 領(lǐng)獎(jiǎng)金"活動(dòng)頁面。
近期收錄2023年6月引用Bioss產(chǎn)品發(fā)表的文獻(xiàn)共305篇(圖一,綠色柱),文章影響因子(IF) 總和高達(dá)1742.4,其中,10分以上文獻(xiàn)34篇(圖二)。
圖一
圖二
本文主要分享引用Bioss產(chǎn)品發(fā)表文章至Nature Nanotechnology, Immunity, Cancer Cell等期刊的7篇 IF>15 的文獻(xiàn)摘要,讓我們一起欣賞吧。
ACS Central Science [IF=18.2]
文獻(xiàn)引用抗體:
bs-0737R; Anti-HIF-1 Alpha pAb | WB,IHC
bs-3494R; Anti-Phospho-mTOR (Ser2448) pAb | IHC,FCM
作者單位:河南大學(xué)藥學(xué)院天然藥物與免疫工程重點(diǎn)實(shí)驗(yàn)室
Nature Communications [IF=16.6]
作者單位:美國圣路易斯華盛頓大學(xué)醫(yī)學(xué)院醫(yī)學(xué)系
摘要:Environmental factors may alter the fetal genome to cause metabolic diseases. It is unknown whether embryonic immune cell programming impacts the risk of type 2 diabetes in later life. We demonstrate that transplantation of fetal hematopoietic stem cells (HSCs) made vitamin D deficient in utero induce diabetes in vitamin D-sufficient mice. Vitamin D deficiency epigenetically suppresses Jarid2 expression and activates the Mef2/PGC1a pathway in HSCs, which persists in recipient bone marrow, resulting in adipose macrophage infiltration. These macrophages secrete miR106-5p, which promotes adipose insulin resistance by repressing PIK3 catalytic and regulatory subunits and down-regulating AKT signaling. Vitamin D-deficient monocytes from human cord blood have comparable Jarid2/Mef2/PGC1a expression changes and secrete miR-106b-5p, causing adipocyte insulin resistance. These findings suggest that vitamin D deficiency during development has epigenetic consequences impacting the systemic metabolic milieu.
BRAIN BEHAVIOR AND
IMMUNITY [IF=15.1]
Anti-ADRB2/FITC pAb | FCM
作者單位:以色列特拉維夫大學(xué)薩克勒醫(yī)學(xué)院臨床微生物學(xué)與免疫學(xué)系
BRAIN BEHAVIOR AND
IMMUNITY [IF=15.1]
bs-2723R; Anti-TREM2 pAb | FCM
作者單位:國家藥監(jiān)局麻醉藥品與精神藥品研究與評(píng)價(jià)重點(diǎn)實(shí)驗(yàn)室
摘要:Inflammatory bowel disease (IBD) is a chronic condition with a high recurrence rate. To date, the clinical treatment of IBD mainly focuses on inflammation and gastrointestinal symptoms while ignoring the accompanying visceral pain, anxiety, depression, and other emotional symptoms. Evidence is accumulating that bi-directional communication between the gut and the brain is indispensable in the pathophysiology of IBD and its comorbidities. Increasing efforts have been focused on elucidating the central immune mechanisms in visceral hypersensitivity and depression following colitis. The triggering receptors expressed on myeloid cells-1/2 (TREM-1/2) are newly identified receptors that can be expressed on microglia. In particular, TREM-1 acts as an immune and inflammatory response amplifier, while TREM-2 may function as a molecule with a putative antagonist role to TREM-1. In the present study, using the dextran sulfate sodium (DSS)-induced colitis model, we found that peripheral inflammation induced microglial and glutamatergic neuronal activation in the anterior cingulate cortex (ACC). Microglial ablation mitigated visceral hypersensitivity in the inflammation phase rather than in the remission phase, subsequently preventing the emergence of depressive-like behaviors in the remission phase. Moreover, a further mechanistic study revealed that overexpression of TREM-1 and TREM-2 remarkably aggravated DSS-induced neuropathology. The improved outcome was achieved by modifying the balance of TREM-1 and TREM-2 via genetic and pharmacological means. Specifically, a deficiency of TREM-1 attenuated visceral hyperpathia in the inflammatory phase, and a TREM-2 deficiency improved depression-like symptoms in the remission phase. Taken together, our findings provide insights into mechanism-based therapy for inflammatory disorders and establish that microglial innate immune receptors TREM-1 and TREM-2 may represent a therapeutic target for the treatment of pain and psychological comorbidities associated with chronic inflammatory diseases by modulating neuroinflammatory responses.
CHEMICAL ENGINEERING
JOURNAL [IF=15.1]
Anti-Calreticulin pAb | IF
作者單位:東南大學(xué)化學(xué)化工學(xué)院
摘要:Ferroptosis is an emerging antitumor treatment modality with the superiority for evading apoptotic cell death pathway. However, how to elevate catalytic efficacy of Fe5-mediated Fenton reaction and efficiently elicit ferroptosis remain enormously challenging. Herein, inspired by hyperthermia-enhanced Fenton reaction kinetics, we firstly designed iron-polyphenol-aspirin-coordinated nanochelates for photothermal-enhanced ferroptosis antitumor immunotherapy. Specifically, we modulated optimal mass feeding ratio of gallic acid (GA), aspirin (ASA), Fe (II) and polyvinylpyrrolidone (PVP) to construct novel nanofibrous GA-ASA-Fe (II) metalchelates named GAFs. The variations in size and structure allowed the nanomedicines to avoid the risk of premature renal clearance in vivo, compared with the reported ultrasmall GA-Fe (II) nanocomplexes (GFs). Under NIR laser irradiation, GAFs could constantly amplify toxic hydroxyl radicals (radical dotOH) generation and deplete excessive GSH to induce more accumulation of lethal lipid peroxidation (LPO), thereby triggering ferroptosis pathway in vitro and in vivo. Besides, the introduction of ASA could inhibit cyclooxygenase-2 (COX-2) and prostaglandin E2 (PGE2), in combination with photothermal-enhanced ferroptosis tumor therapy to induce immunogenic cell death (ICD), promote maturation of dendritic cells (DCs) and activate cytotoxic T cells for synergistic antitumor immunotherapy. GAFs with laser irradiation exhibited the capacity of inhibition of pulmonary metastasis. This work presented a strategy for incorporating small molecule immunomodulator into the metal-polyphenolic coordination to ameliorate its deficiencies, thereby inspiring a new design concept for tumor treatment.
CHEMICAL ENGINEERING
JOURNAL [IF=15.1]
Anti-CD163 pAb | IF,ICC
摘要:Smart hydrogel dressings capable of simultaneously highly effective antimicrobial, anti-inflammatory, and promoting re-epithelialization and angiogenesis are urgently needed for the management of diabetic wounds. Herein, a H2S-releasing multifunctional hydrogel was developed by utilizing the dynamic Schiff base reaction between carboxymethyl chitosan (CMC) and polyhexamethylene guanidine (PHMG)-modified aldehyde F108 (PFC). Diallyl trisulfide (DATS) was encapsulated into the PFC nanoparticles. Apart from possessing the essential properties necessary for an idealized hydrogel dressing, such as excellent injectability, tissue adhesion, self-healing, and stimulus–response degradation, the DATS@PFC&CMC also utilized the synergistic effect of the PHMG and DATS to provide an efficient antimicrobial effect; the H2S was slowly released from the DATS under the action of GSH and exerted excellent anti-inflammatory effects, by inhibiting the expression of p-ERK and p-STAT3 in activated macrophages, and promoting macrophage polarization to the M2 phenotype. Strikingly, following the completion of the efficient antimicrobial and anti-inflammatory effects, the continuously generated H2S further significantly accelerated the proliferation, migration, and vascularization of endothelial cells by extending the activation of the p-p38 and p-ERK1/2. Owing to superior performances, DATS@PFC&CMC significantly promoted the healing of diabetic wounds induced by streptozotocin with good biocompatibility. This study demonstrates that DATS@PFC&CMC is a versatile hydrogel dressing with great potential for the management of diabetic wounds.
CHEMICAL ENGINEERING
JOURNAL [IF=15.1]
文獻(xiàn)引用抗體:
bs-43042P; Recombinant SARS-Cov-2 Spike S1 protein (L18F, T20N, P26S, D138Y, R190S, K417T, E484K, N501Y, D614G, H655Y), His (HEK293);
bs-43049P; Recombinant SARS-Cov-2 Spike S1 protein (T19R, G142D, del157/158, L452R, T478K, D614G, P681R), His (HEK293);
bs-43041P; Recombinant SARS-Cov-2 Spike S1 protein (D80A, D215G, del241/243, K417N, E484K, N501Y, D614G), His (HEK293);
作者單位:哈爾濱醫(yī)科大學(xué)生物醫(yī)學(xué)學(xué)院
※ 點(diǎn)擊這里查看往期單月Bioss抗體產(chǎn)品文獻(xiàn)引用列表